Sequent Scientific Limited — Updates, 20-05-2025: Press Release

SeQuent Scientific has announced a board meeting on the financial results for the quarter and half-year. Q4 FY25 revenues rose 11.2% to ₹401.7 Cr, with EBITDA up 38.7% at ₹56.9 Cr, driven by better profitability and operational efficiency. FY25 revenues increased 13.3% to ₹1,551.4 Cr, with EBITDA up 86.6% at ₹199.3 Cr and margin expansion of 500 bps. The merger with Viyash Life Sciences is on track, combining FY25 revenues of ₹3,009.4 Cr and EBITDA growing 65.7%, with ongoing synergy and integration efforts to boost growth.